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A summary of the changes to PCa grading from the original 
Gleason grading system to the latest prognostic grade grouping 
is presented. This review also includes a discussion of the clinical 
significance of the percentage of Gleason patterns 4 and 5.
THE 2005 AND 2014 MODIFIED GLEASON GRADING 
SYSTEMS
One of the biggest changes to the Gleason grading system was the 
classification of Grades 1 and 2. Grade 1 tumors are generally benign, 
and Grade 2 tumors do not appear to differ from those classified as 
Grade 3. In 2005, Grade 2 was recommended to be used “rarely, if ever,” 
and in the 2014 modified Gleason grading system, grading started 
from 3. This modification accounted for some of the observed rises in 
Gleason scores. A second change causing an increase in Gleason scores 
was the narrowing of the definition of Gleason 3 and concomitant 
expansion of Gleason 4.
From the 2005 to the 2014 consensus conferences, the histologic 
criteria for Gleason patterns 3 and 4 changed, resulting in the reduction 
of pattern 3 and expansion of pattern 4.2 In the original system, pattern 
3 included some cribriform as well as poorly formed glands.5 Only 
well-formed discrete glands are included in pattern 3 in the 2014 
modified Gleason grading system. In particular, cribriform glands 
lacking basal cells, independently of their morphology and size, are 
considered as pattern 4 in the 2014 modified Gleason system.1,2,6–15 
Fused, poorly formed, and glomeruloid glands are part of the 
morphologic spectrum of the current Gleason pattern 4.
As some patterns that were previously included in Gleason pattern 
3 are now considered pattern 4, PCas with a GS of 3 + 3 = 6 based on 
the ISUP 2014 modified system have a far better prognosis than PCas 
INTRODUCTION
Treatment of prostate cancer  (PCa) is based on the clinical and 
pathological features that predict the course of the disease. The risk of 
local or systemic recurrence is usually based on data obtained from 
prostate needle biopsy or radical prostatectomy (RP) specimens. The 
Gleason grading system is one of the most important prognostic 
factors.1–3
In 1966, DF Gleason created a grading system for PCa based on 
tumor architectural patterns.4 Dr. Gleason recognized the heterogeneity 
of PCa by assigning two grades to the two most common architectural 
patterns, reported as the Gleason score (GS).4 Dr. Gleason reported 
that the presence of more than two architectural patterns was quite 
rare to allow for an accurate evaluation of the prognostic role of the 
third most prevalent pattern (i.e., the tertiary pattern).5
The management of PCa has changed since the original system 
was proposed. In particular, patients in the 1960s and 1970s were not 
treated with RP because they presented with advanced disease and 
because of the greater morbidity associated with surgery; therefore, 
grading of RPs with multiple tumor foci and tertiary patterns was 
not fully investigated by Dr. Gleason. With the PSA screening and 
18-gauge needle biopsies, pathologists faced new issues, such as 
how to report multiple cores with PCa of different GSs and how 
to grade small amounts of PCa. Pathologists needed guidance for 
applying the grade to newly described histological patterns and 
variants of PCa, and modifications of the original Gleason system 
were needed to reflect the modern practice. The Gleason grading 
system has undergone changes as a result of two International 
Society of Urological Pathology (ISUP) consensus conferences held 
in 2005 and 2014.4,6
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with a GS 6 based on the original Gleason system.16 The concordance 
between biopsy and RP grades has also improved.17–19
A further modification to the grading system in 2005 with regard 
to needle biopsy was that for high-grade tumors, the lower grade or 
pattern should not be included in the GS if it is <5% of the tumor. In 
needle biopsy findings with three distinct patterns, the most prevalent 
pattern is combined with the highest grade to form the GS, thus 
discarding to the second most common pattern.4 Grading is based on 
the “first plus the worst,” that is, the most prevalent pattern plus the 
highest grade, such that if patterns 3, 4, and 5 are present in that order 
of prevalence, the grade is 3 + 5 = 8.
A recommendation from the 2014 consensus conference was 
that the percentage of pattern 4 is recorded in all GS 7 (3 + 4, 4 + 3) 
tumors.6,20 This further stratifies GS 7 and allows for identification of 
tumors with a limited (i.e., ≤10%) or extensive (i.e., >75%) amount of 
pattern 4.21 The practical value is that selected patients with GS 7 (3 + 4) 
and a small amount of pattern 4 (such as ≤10%) may be still enrolled 
in active surveillance programs.22–24
Main limitations of the 2005 and 2014 modified Gleason scoring 
systems
From a clinical perspective, the 2005 and 2014 modified Gleason 
systems are suboptimal due to several reasons as follows:2,25–29
1. Patients with GS 3 + 3 = 6 are considered to have intermediate-risk 
cancer, even though GS 6 is the lowest score used on prostate 
biopsies
2. The category of GS 7 includes tumors with 3 + 4 = 7 and 4 + 3 = 7, 
with studies showing better outcome for GS 7 with primary 
pattern 3 versus 4
3. GS 9–10 tumors have a poorer prognosis than that seen with GS 
4 + 4 = 8 tumors30,31
4. Different grouping systems have been used to combine tumors 
with different GSs for treatment as well as for estimated prognosis.
GRADE GROUPS
A novel grading system for PCa was adopted in 2014 to address some of 
the above limitations, which included five distinct Grade Groups (GGs), 
from 1 to 5 (Table 1).28 The clinical importance of the GGs has been 
shown in clinical studies (Table 2).28,32–43  However, it has been suggested 
that the GG system should be used in parallel with the 2014 Gleason 
grading system.44,45
Genomics and grade group
A genomic study using whole exome and genome sequencing 
data from 426 localized PCas treated by RP supports the clinical 
significance of the prognostic GGs.46 This study showed an increase in 
the frequency of both genomic deletions and amplifications associated 
with an increasing risk strata and of nonsynonymous point mutations. 
Low-risk GG 1 tumors were haploid, whereas GG 2–5 tumors showed 
an increasing frequency of polyploidy. Distinct genomic profiles 
among the five GGs were seen with Principal Component Analysis, 
giving support to GG 1 through GG 3 being distinct categories; 
however, there is genomic similarity between GG 4 and GG 5.46
Excellent prognosis for GG 1
PCa with GS 6 is not considered to be a lethal cancer, even though 
tumor progression and/or lymph node deposits have been documented 
in a small number of patients.47,48 In a study of 395 RPs, where 
151 patients were GG 1 (i.e., GS 3 + 3 = 6), four of the patients with GG 
1 (2.6%) showed disease recurrence and progression, three were alive 
after a mean follow-up of 82 months, and one died after 108 months.40 
A histologic review of the slides of these four patients resulted in an 
upgrade of three cases to GG 2 (i.e., GS 3 + 4 = 7), while the fourth 
case was still considered as a GG 1  (i.e., GS 3 + 3 = 6) albeit with 
positive surgical margins. Aside from the three patients with a minor 
component of pattern 4 (two cribriform and one glomeruloid) and 
one patient with positive surgical margins, the other 147 patients were 
GG 1 (i.e., GS 3 + 3 = 6) and remained alive without tumor relapse or 
recurrence after a follow-up period of 8–10 years.
Such observations are in agreement with another study, in which 
no disease-specific death or metastasis was observed in patients 
with GS  ≤6 PCa at RP.49 Similarly, an earlier study concluded that 
lymph node metastases do not occur with GS ≤6 tumors, and Gleason 
patterns 4 or 5 are needed for metastatic PCa.50 It should be noted that 
GS 6 tumors have cancerous morphology and exist on a molecular 
continuum with higher GSs.51
Future studies
Additional studies are needed to investigate the clinical utility of the 
new GG system in prospective clinical trials. Studies correlating current 
PCa diagnosis methods with multiparametric magnetic resonance 
imaging (mpMRI) and PCa GG are yet to be conducted. It is hoped 
that information will be derived on whether mpMRI can also be used 
to determine the proportion of high-grade cancer and GGs.52,53 This 
will have a great importance in the multidisciplinary management 
of patients with PCa, including treatment by urologists, oncologists, 
uropathologists, and radiation oncologists.1
CLINICAL SIGNIFICANCE OF THE PERCENTAGE OF 
GLEASON PATTERNS 4 AND 5
In tumors with GS >7, the percentage of Gleason patterns 4 and 5 has 
clinical significance from a prognostic perspective.21 In particular, the 
presence of even a smaller amount of Gleason pattern 5 (tertiary) is 
associated with a greater risk of biochemical recurrence. Therefore, the 
presence of Gleason patterns with unfavorable prognosis in localized 
PCa, such as Gleason pattern 5, is known to be associated with an 
Table 1: Prognostic grade groups
Grade group Description
GG 1 (GS ≤6) PCa composed only of well‑formed and separated glands
GG 2 (GS 3+4=7) PCa with predominantly well‑formed and separated glands and a lesser component of poorly formed/fused/glomeruloid/
cribriform elements
GG 3 (GS 4+3=7) PCa with predominantly poorly formed/fused/glomeruloid/cribriform elements with a minor component of well‑formed and 
separated glands
GG 4 (GS 4+4=8, 3+5=8, or 5+3=8) PCa with poorly formed/fused/glomeruloid/cribriform glands or tumors with well‑formed and separated glands and 
lesser component without glands, or tumor predominantly without glands with a lesser component of well‑formed and 
separated glands
GG 5 (GS 9 or 10) PCa without gland/lumen or with necrosis, with or without poorly formed/fused/glomeruloid/cribriform elements
GG: grade group; GS: Gleason score; PCa: prostate cancer
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increased risk of tumor recurrence and metastasis after primary 
treatment with RP, external beam radiation therapy, or brachytherapy.54 
According to one study, one of the most accurate predictors of patient 
outcome is the combined percentage of Gleason patterns 4 and 5, with 
this method having apparent superiority over GS for identification of 
patients with an increased risk of disease progression.55 Evaluation of 
the combined percentage of Gleason patterns 4 and 5 in RP specimens 
is recommended, and the percentage of high-grade cancer in a RP 
specimen should be considered during assessment of patient prognosis 
and the selection of potential treatment options.55
There is evidence to support the clinical utility of including the 
percentage of high-grade tumor component in the pathology report.21,56 
However, there is no agreement on how the percentage of Gleason 
patterns 4 and 5 is to be recorded. For instance, it could be in intervals of 
10% or of <5%, 5%–10%, 10%–25%, 25%–50%, 50%–75%, and >75%.24
Tertiary pattern 5, grade groups, and integrated quantitative Gleason 
score
Several studies have evaluated the prognostic significance of tertiary 
Gleason pattern 5 both in biopsy and in RP.57–75 The method for 
reporting the presence of tertiary Gleason pattern 5 on RP specimens 
has been controversial.2 The 2005 ISUP consensus conference 
recommended the inclusion of Gleason pattern 5 in the final GS if it 
is >5% of the tumor, or to consider it as a tertiary pattern if it is <5% 
of the tumor.4 According to the 2014 ISUP consensus conference, 
tertiary patterns should only be recorded in RP specimens with either 
3 + 4 = 7 or 4 + 3 = 7.2
It is unclear how to integrate small Gleason pattern 5 components 
into GG classification. Concerning the tertiary pattern 5 on RP 
specimens with GS 3 + 4 = 7 and 4 + 3 = 7 tumors, these would be 
considered to be GG 2 and GG 3, respectively, with a minor higher 
grade component, or as GGs >2 or >3.2,76,77 Following the 2014 ISUP 
consensus conference, publication of a separate report was planned, 
with recommendations relating to special scenarios, such as patients 
with a small percentage of high-grade tumor, tertiary grade patterns, 
utilization of pattern 4 percentage, and case-  versus core-level 
reporting.6 Gleason 3  +  5  =  8 cancer is a type of special case, and 
this biopsy finding predicts an outcome similar to 4 + 4 = 8 tumors, 
suggesting that 3 + 5 = 8 belongs to GG 4.78
Detection of cribriform glands confers a 6-fold odds ratio of 
PSA failure and an increased risk of metastasis or death. An ongoing 
shortcoming of the GG grading system is that large gland spaces with 
cribriform-to-papillary-to-almost-solid cell arrangements  (without 
basal cells, or intraductal carcinoma if basal cells are present) are 
graded as Gleason pattern 4, which is identical to the fused small 
gland pattern, yet the outcome for cribriform/intraductal glands is 
demonstrably more adverse.8,15,78
Since 2011, more than a dozen studies have confirmed the uniquely 
adverse implications of the cribriform pattern.1 As a result, urologic 
pathology reports are required to specify whenever a cribriform growth 
pattern is present. One of the main practical implications of cribriform/
intraductal growth is preclusion of the patient’s treatment choice of 
active surveillance. Ultimately, the presence of these growth patterns 
will need to be incorporated in the GG system.
An analysis of the role of the percentage of Gleason patterns 4 and 
5 in a large cohort of more than 10 000 patients has demonstrated the 
importance of the percentage of these Gleason patterns in predicting 
PCa aggressiveness.79 A Gleason 5 component correlated with cancer 
progression and predicted, independently of its amount, further 
deterioration in the clinical course.79 A system for integration of both 
patterns into a continuous numerical scale or score, i.e.,  integrated 
quantitative  (IQ)  –  Gleason score, was developed that provides a 
method for combining quantitative Gleason grading and tertiary 
Gleason patterns into a single prognostic value.79 This approach may 
enable clinicians to utilize the minor component of high-grade tumors 
and tertiary grade patterns in association with the PCa Gleason grading 
system, including the GGs.
CONCLUSIONS
The proposed GG system reduces PCa grades to the lowest number of 
grades, each being associated with a unique prognosis. This simplified 
grading system of five groups allows for more accurate stratification 
of patients than Gleason systems, with the potential for reducing 
overtreatment of PCa. The shift from a lowest value of 6 to 1 has a 
Table 2: Studies showing the clinical significance of the grade groups system
Study Patient (n) Type of specimens Median follow‑up Prognosis (end point of the study)
Pierorazio et al.28 7869 Biopsy (preprostatectomy), RP 2 years Biochemical recurrence‑free survival
Epstein et al.32 26 346 (20 845 
RP + 5501 bx)
Biopsy (preprostatectomy), RP, Biopsy (preradiation 
therapy)
3 years Biochemical risk‑free survival
Spratt et al.33 3694 Biopsy (preprostatectomy), RP 52.7 months Biochemical recurrence‑free survival
Spratt et al.34 847 Biopsy (preradiation therapy) 88 months Biochemical recurrence‑free survival, 
DMFS, PCSS
Berney et al.35 988 Biopsy (preprostatectomy), biopsy (preradiation therapy) 10 years PCa‑specific death
Samaratunga et al.36 2079 Biopsy (preprostatectomy) 44 months Biochemical recurrence‑free survival
Delahunt et al.37 496 Biopsy (preradiation therapy and androgen ablation) 6.5 years (minimum) DMFS, PCSS, biochemical 
recurrence‑free survival
Loeb et al.38 5880 RP, biopsy (preradiation therapy) 4.6 years Biochemical recurrence‑free survival
Minardi et al.39 395 RP 8–10 years Biochemical recurrence‑free survival
Leapman et al.40 10 529 Biopsy (preprostatectomy), RP, biopsy (preradiation 
therapy)
81 months PCa‑specific mortality and bone 
metastasis
He et al.41 331 320 Biopsy (preprostatectomy), RP, biopsy (preradiation 
therapy)
38 months PCa‑specific mortality
Dell’Oglio et al.42 9728 Biopsy (preprostatectomy), RP 5.8 years Clinical recurrence
Ham et al.43 1768 (721 biopsy 
+ 1047 RP)
Biopsy (preprostatectomy), RP 3 years for biopsy, 
4 years for RP
PCa‑specific mortality
CR: clinical recurrence (defined as local and/or nodal recurrence [recurrence in prostatic bed and/or pelvic lymph nodes], retroperitoneal recurrence, or systemic recurrence [skeletal 
and/or visceral relapse]); DMFS: distant metastasis‑free survival; PCa: prostate cancer; RP: radical prostatectomy; PCSS: prostate cancer‑specific survival
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positive impact from a psychological perspective on patients’ disease 
awareness, thus facilitating patients’ choice of treatment, including 
prostatectomy, targeted cryoablation, radiotherapy, hormonal therapy, 
and active surveillance. In particular, GS 6 cancer is characterized by 
indolent growth with an excellent prognosis. However, it should still be 
considered potentially metastatic since it is rarely localized so as not to 
mislead patients seeking a cure.80 The GG system has been considered 
by the international community to be a new grading system, although 
most urologic pathologists consider it to be a novel grouping of the 
2014 ISUP modified Gleason system.
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